European Society of Cardiology - 2005 1 1 Cardiovascular diseases in women.

Slides:



Advertisements
Similar presentations
ESC & cardiovascular prevention policy John F Martin.
Advertisements

Prof Desmond Sheridan ESC mission To improve the quality of life of the European population by reducing the impact of cardiovascular disease.
The Risk Concept in health care Definition of a risk factor  a disease precursor associated with a higher than average morbidity or mortality rate. John.
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:
Women’s Heart Policy October, 2004 Gastein John O’Toole (personal capacity) Perm Rep of Irl to EU.
 Heart disease is women’s No. 1 killer  Stroke is women’s No. 3 killer.
10 Points to Remember on Lifestyle Management to Reduce Cardiovascular RiskLifestyle Management to Reduce Cardiovascular Risk Summary Prepared by Elizabeth.
Living with and beyond treatment for cancer – the challenge for secondary care Nigel Acheson Medical Director Peninsula Cancer Network.
The European Pact for Mental Health and Well-being Participants in the EU high-level conference "Together for Mental Health and Wellbeing“ (Brussels, 13.
Level Health Equally Well Key findings from a literature review informing collaborative efforts to improve the physical health outcomes of people with.
Basma Y. Kentab MSc. Department of Clinical Pharmacy May 2014.
Brandi Cooke Student Intern 3 rd National Summit on Preconception Health and Health Care June 12-14, 2011 Factors Affecting the Willingness of Counselors.
Journal Club Alcohol and Health: Current Evidence July–August 2004.
Effectiveness of interactive web-based lifestyle program on prevention of cardiovascular diseases risk factors in patient with metabolic syndrome: a randomized.
The Role of the Nurse in Implementing CVD Prevention Guidelines Noeleen Fallon Clinical Nurse Specialist in Cardiac Rehabilitation AMNCH, Tallaght, Dublin.
Rare Diseases Working Group Luzern, 24 September 2010.
Biology in Focus, HSC Course Glenda Childrawi, Margaret Robson and Stephanie Hollis A Search For Better Health Topic 11: Epidemiology.
Chapter 17 Nursing Diagnosis
Women's Health Study: Low-Dose Aspirin in Primary Prevention Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Dr.
Incidence and Prognostic Implications of Stable Angina Pectoris Among Women and Men Harry Hemingway FRCP, Alison McCallum MB/BS, Martin Shipley MSc, Kristiina.
Cardiac Rehabilitation Are you or someone you know missing the benefits of Cardiac Rehabilitation? July
CHAPTER 24: Converging Issues in Heart Disease, Stroke, and Alzheimer’s Disease in Women.
ADAMOS ADAMOU, MEDICAL ONCOLOGIST MEMBER OF THE EUROPEAN PARLIAMENT.
Epilepsy in Europe 26th of August Dr. Mat Muijen -Regional Adviser Mental Health.
Inequalities in coronary heart disease treatment Professor Azeem Majeed University College London.
European guidelines on the management of stable coronary artery disease Key points & new position for Ivabradine and Trimetazidine ESC 2013 Montalescot.
AN ASSESSMENT OF THE PRIMARY PREVENTION CONTROL PROGRAM OF PHC PREVENTIVE CARDIOLOGY CLINIC AMONG PATIENTS AT RISK FOR CVD: A Retrospective Cohort Study.
Cardiovascular Disease in Women Module I: Epidemiology.
Cardiovascular Disease in Women Module V: Prognosis and Treatment Outcomes.
Heart Failure Programs Europe and Belgium Sandra Martin Clinical Nurse Specialist UZ Leuven, Belgium.
Developing Cardiac Rehabilitation in Vietnam Dr Juliette Hussey School of Medicine Trinity College Dublin Ireland.
Self-reported cognitive and emotional effects and lifestyle changes shortly after preventive cardiovascular consultations in general practice Dea Kehler.
Why value “measurement” is critical to the future of the meetings industry development Isabel Bardinet, CEO ESC JMIC, Paris, May 2015.
Fenofibrate Intervention and Event Lowering in Diabetes FIELDFIELD Presented at The American Heart Association Scientific Sessions, November 2005 Presented.
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.
Acute Stroke: Principles of Modern Management A program of the American Academy of Neurology The AAN Acute Stroke Management courses are supported in part.
Can pharmacists improve outcomes in hypertensive patients? Sookaneknun P (1), Richards RME (2), Sanguansermsri J(1), Teerasut C (3) : (1)Faculty of Pharmacy,
Use of Summary Measures in the US Healthy People and Healthiest Nation Initiatives Richard J. Klein US Centers for Disease Control and Prevention National.
Databases Using them to study MS in the UK. Proposed research using: GPRD (General Practice Research Database) MSNTC Northwood Database.
Alcohol Screening and Brief Interventions for Patients with Non-communicable Diseases Thomas F. Babor Department of Community Medicine University of Connecticut.
Innovations in Management of Cardiovascular Disease for Global Health
Pharmacoeconomic insight in current dyslipidemia treatment Jana Skoupá, MD, MBA CARDIONALE Prague,
European Heart Health Charter Official Launch 12 June 2007 European Parliament - Brussels "Every child born in the new millennium has the right to live.
 What organizations collect and provide information on infectious diseases? 
Models/ Health Experts
European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003 EUROPA.
Carina Signori, DO Journal Club August 2010 Macdonald, M. et al. Diabetes Care; Jun 2010; 33,
Women reaching equality in health, despite the differences Nowadays women remain the largest CAD population subgroup being under-diagnosed and under-treated.
NHS Health Check programme An opportunity to engage 15 million people to live well for longer Louise Cleaver National Programme Support Manager.
Chapter 7: Epidemiology of Chronic Diseases. “The Change You Like to See….” (1 of 3) Chronic diseases result from prolongation of acute illness. – With.
Cardiovascular Risk: A global perspective
How Do We Individualize Guidelines in an Era of Personalized Medicine? Douglas K. Owens, MD, MS VA Palo Alto Health Care System Stanford University, Stanford.
BUILDING INTEGRATED HEALTH SERVICE DELIVERY NETWORKS
Richard Murrugarra – Centurion
Landon Marshall, Pharm. D. , Matt Hill, Pharm. D. , Jim Wilson, Pharm
A Search For Better Health Topic 11: Epidemiology
Hypertension November 2016
American Heart Month Resources:
Musculoskeletal Health in Europe
How to Promote Women Awareness to Heart Disease and the Role for Women
Ageing with ideal cardiovascular risk factors
Select Topics in Cardiovascular Medicine
SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.
Section III: Neurohormonal strategies in heart failure
Policy Change Department of Veterans Affairs
Hypertension November 2016
Epidemiological Terms
Cardiovascular Disease in Women Module IX: Presentation Resources and Internet Resources This slide set was updated April 2008.
Dr Timothy Armstrong Coordinator
Section C: Clinical trial update: Oral antiplatelet therapy
Presentation transcript:

European Society of Cardiology Cardiovascular diseases in women

2 2 Cardiovascular diseases in women Fast facts Cardiovascular disease (CVD) is the primary cause of death in European women It kills a higher percentage of women (55%) even than men (43%) and more than all cancers combined. However, there still exists a disturbing gap in the knowledge, understanding, and general awareness of cardiovascular disease in women, across medical audiences as a whole. Cardiovascular disease (CVD) is the primary cause of death in European women It kills a higher percentage of women (55%) even than men (43%) and more than all cancers combined. However, there still exists a disturbing gap in the knowledge, understanding, and general awareness of cardiovascular disease in women, across medical audiences as a whole.

European Society of Cardiology The impact of underestimation As a frightening consequence of the underestimation of cardiovascular diseases in women, risk factors for heart disease are raising among women > Specific campaigns on prevention of cardiovascular diseases in women are needed

European Society of Cardiology The heart of men and women Clinical and epidemiological studies have shown that men and women with cardiovascular disease differ with respect to disease processes, clinical presentations, and outcomes.

European Society of Cardiology What is different in CVD in Women? Women develop heart disease later in life than men; Women are more likely to have co-morbidities that may mask symptoms of heart disease; Symptoms of a heart attack in women may differ from those in men, leading to a misdiagnosis of the disease; Post MI women who are more likely to have a stroke or another heart attack than men; 42% of women die within one year following a heart attack vs. 24% of men. Women develop heart disease later in life than men; Women are more likely to have co-morbidities that may mask symptoms of heart disease; Symptoms of a heart attack in women may differ from those in men, leading to a misdiagnosis of the disease; Post MI women who are more likely to have a stroke or another heart attack than men; 42% of women die within one year following a heart attack vs. 24% of men.

European Society of Cardiology The impact of CVD in Women As compared to men, women have a poorer prognosis and experience greater disability moreover they: Are at a higher risk of psychosocial distress; Have a greater need for instrumental support and social support; Have an altered perception of risk; Demonstrate the need for specific rehabilitation programs, tailored to their needs. Davidson et al 2001

European Society of Cardiology Do we have data to cure the heart of women? The enrolment of women in clinical trials came under scrutiny in the mid-1980s with the realisation that less information about treatment was available for women with cardiovascular disease than for men with the disease.

European Society of Cardiology Gender specific differences in the effects of treatment To determine definitively whether an intervention or therapy affects women and men differently, the trial must include a number of women to ensure that the study has the statistical power to evaluate the effect of the intervention in each sex and to compare the magnitude of these effects.

European Society of Cardiology Moving in the right direction In 1993 the NIH Revitalization Act required the inclusion of women in every clinical trial involving a disorder that affects women to: “….ensure that the trial is designed and carried out in a manner sufficient to provide for a valid analysis of whether the variables being studied in the trial affect women [and men] differently." In 1993 the NIH Revitalization Act required the inclusion of women in every clinical trial involving a disorder that affects women to: “….ensure that the trial is designed and carried out in a manner sufficient to provide for a valid analysis of whether the variables being studied in the trial affect women [and men] differently."

European Society of Cardiology Conclusion Cardiovascular diseases are a major cause of morbidity and mortality female patients; The pivotal role of CVD in women is under recognized by citizens and physicians alike; The distinguishing aspects of CVD in women are not familiar to medical professionals. Cardiovascular diseases are a major cause of morbidity and mortality female patients; The pivotal role of CVD in women is under recognized by citizens and physicians alike; The distinguishing aspects of CVD in women are not familiar to medical professionals.

European Society of Cardiology A need for action Need for a fair gender representation in clinical trials; Promote research both at clinical and basic level to understand more on CV Physiology in females; Assess if gender specific differences exist in the response to therapy. Need for a fair gender representation in clinical trials; Promote research both at clinical and basic level to understand more on CV Physiology in females; Assess if gender specific differences exist in the response to therapy.

European Society of Cardiology Objectives Three main goals need to be achieved to impact CVD in women: Education of the Profession Education of the Patients Collection of epidemiological and outcome data Three main goals need to be achieved to impact CVD in women: Education of the Profession Education of the Patients Collection of epidemiological and outcome data

European Society of Cardiology The ESC effort to fill the gap The European Society of Cardiology is committed to provide education and research on the topic of CVD in women and has therefore organized a targeted initiative. Women at Heart, the ESC program on CVD in women will act in synergy with existing initiatives that are taking place in Europe and in the USA

European Society of Cardiology Committed to Improving Heart Health for Women An initiative of the European Society of Cardiology

European Society of Cardiology Primary target audience = Medical Profession 2.Focus on the scientific underpinning of the topic 3.ESC strive to provide evidence based information for various stakeholders 4.Not a PR campaign Women at Heart Distinguishing profile of the ESC initiative

European Society of Cardiology Women at Heart Policy Conference on CVD in Women Meeting of more than 62 experts and representatives of National Societies, Working Groups and Associations Production of a scientific and political statement on the topic, to be published in the European Heart Journal June 2005, European Heart House

European Society of Cardiology Women at Heart European Data on CVD in Women Analysis from the EuroHeart Survey databases On epidemiology of CVD in women and women’s access to treatment > Preparation of a comprehensive summary of results/ original educational material

European Society of Cardiology Women at Heart ESC Congress 2005 S pecial focus on women and CVD, in the main sessions, through dedicated sessions, oral abstracts and posters presentations Specific information on risk factor reduction through lifestyle improvements, at the ESC public event, ‘For Your Heart’s Sake, 2-4 September 2005, Stockholm, Sweden. 3-7 September 2005 Stockholm, Sweden

European Society of Cardiology Women at Heart Next Steps Through the ESC network of 49 affiliated countries, National Cardiac Societies are taking up the challenge and adapting the initiative at a national level. Increased awareness of women’s CVD patterns Improved quality of care of women with heart disease and stroke across Europe.

European Society of Cardiology Show your support, Wear the symbol!